A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This research study is investigating the long-term safety of a medication called pirtobrutinib. It's for people in the UK who have chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) and have already had treatment for their condition. Crucially, this study is only open to individuals who are currently taking part in a specific previous research study (known as J2N-MC-JZNN/LOXO-BTK-20020). The main goal is to continue to monitor the effects of pirtobrutinib over a longer period, ensuring it remains as safe as possible for patients. Participants will receive their medication every four weeks, and the study is expected to last for approximately five years.
At a glance
What is this study about?
This study is about a medication called pirtobrutinib, and it focuses on understanding its long-term safety for individuals living with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). Both CLL and SLL are types of cancer that affect white blood cells, a crucial part of your body's immune system. If you have either of these conditions and have already received some form of treatment, this study might be relevant to you.
The main purpose of this research is to keep a close eye on people who have been taking pirtobrutinib for a while. We already know something about this medication from earlier studies, but it's important to collect more information over a longer period. This helps doctors and researchers understand if there are any long-term effects or side effects that weren't apparent in shorter studies. Gathering this information helps ensure that treatments are as safe and effective as possible for patients.
This particular study is designed for a very specific group of people: those who are currently participating in a previous study involving pirtobrutinib (referred to by its trial code J2N-MC-JZNN/LOXO-BTK-20020). It offers these participants the chance to continue taking their study medication or to continue receiving follow-up checks. By extending the follow-up period, the researchers can gather valuable data on the safety of pirtobrutinib over many years, which can help in developing better treatments in the future.
Key takeaways
- This study is for long-term monitoring of pirtobrutinib safety.
- Only participants from a previous pirtobrutinib study can join.
- It involves regular check-ups and receiving mediation every four weeks.
- The study is expected to run for about five years.
- It focuses on chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL).
Who may be eligible?
To be considered for this study, there's one very important requirement: you must currently be taking part in another study that’s specifically for pirtobrutinib. That study is known by its code: J2N-MC-JZNN/LOXO-BTK-20020.
If you are not currently in that specific pirtobrutinib study, unfortunately, you won't be able to join this one. This study is essentially an extension of the previous one, designed to allow participants to continue their treatment or monitoring.
- Are you 18 years old or older?
- Are you currently diagnosed with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)?
- Are you currently an active participant in the pirtobrutinib study known as J2N-MC-JZNN/LOXO-BTK-20020?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you join this study, you will continue to receive the medication called pirtobrutinib. This medication will be given to you every four weeks. The study staff will regularly check in with you to monitor your health and how you are responding to the treatment. These check-ups are also important for observing any potential side effects. The entire study is expected to last for about five years. During this time, you'll have scheduled visits and assessments to track your progress and ensure your safety.
Potential risks and benefits
Locations (53)
- Mitchell Cancer InstituteMobile, United States· Not yet recruiting
- Arizona Oncology Associates, P.C. - HOPETucson, United States· Not yet recruiting
- Cancer Specialists, LLCJacksonville, United States· Not yet recruiting
- Minnesota Oncology Hematology, P.A.Coon Rapids, United States· Not yet recruiting
- Cayuga Cancer CenterIthaca, United States· Not yet recruiting
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New YorkNew York, United States· Recruiting
- Oncology Hematology Care IncCincinnati, United States· Not yet recruiting
- Texas Oncology - ParisFort Worth, United States· Not yet recruiting
- US Oncology - Texas OncologyKyle, United States· Not yet recruiting
- Liverpool HospitalLiverpool, Australia· Not yet recruiting
- The Alfred HospitalMelbourne, Australia· Not yet recruiting
- LKH - Universitätsklinikum der PMU SalzburgSalzburg, Austria· Not yet recruiting
+41 more sites — see the official record for the full list.
Common questions
What is pirtobrutinib?
Pirtobrutinib is a medicine being studied for conditions like chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL).
Who can join this study?
You can only join this study if you are already taking part in a specific previous pirtobrutinib study (J2N-MC-JZNN/LOXO-BTK-20020).
How long will the study last?
This study is expected to last for approximately five years.
What will I have to do if I join?
You will continue to receive pirtobrutinib every four weeks and have regular check-ups to monitor your health.
Will I get a different type of treatment?
No, this study is about continuing to monitor pirtobrutinib for those already taking it; it does not involve new or alternative treatments like idelalisib.
How to find out more
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.